IMPAM   23988
INSTITUTO DE INVESTIGACIONES EN MICROBIOLOGIA Y PARASITOLOGIA MEDICA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
- ?In vitro and in vivo effect of lumefantrine on Trypanosoma cruzi, the etiologic agent of Chagas disease?
Autor/es:
GARCÍA-BOURNISSEN F; GULIN JE; ALTCHEH J; SOLANA ME
Lugar:
Cape Town
Reunión:
Congreso; 17th World Congress of Basic and Clinical Pharmacology (WCP2014); 2014
Resumen:
Background: Lumefantrine (LMF) is an anti-malarial drug with a long half life and still unclear mechanism of action. Lumefantrine activity against kinetoplastids has not been fully studied.The objective of this study was to evaluate LMF activity against T cruzi. Methods: in vitro studies: Vero cells were infected with T cruzi trypomastigotes, VD strain, for 24hs. Cultures were then exposed to LMF (0.5 to 50 microM) for 72hs. After treatment, cells were stained with Giemsa, and infected cells and number of amastigotes per cell were counted using ImageJ software. In vivo studies: 16 female BALB/c mice (4 per group) were infected with 500 trypomastigotes (VD strain), and LMF administered at peak parasitaemia, 12 days post infection (dpi), for 20 days. Group 1 received 80 mg/Kg/day LMF, Group 2 160 mg/kg/day LMF, Group 3 was the untreated control, and Group 4 was a positive control treated with benznidazole 100 mg/kg/day. Mice weight, parasitaemia and mortality were registered daily. Results: No effect of LMF on T cruzi infection was observed in the in vitro studies, except for the 50 microM dose which showed significant parasite reduction (p